Introduction: Portal Vein Embolization (PVE) is gold standard strategy to increase Future Liver Remnant (FLR) at level of Kinetic Growth Rate (KGR) about 2.3 cc/day and prevent posthepatectomy liver failure (PHLF) in patients to underwent major liver resections. Up to 30% of patients with liver malignances still couldn't underwent surgery after PVE due to tumor progression and/or insufficient FLR regeneration during waiting period. Currently there are no methods that resolve both mentioned issues. Method: Six initially unresectable, due to small FLR, patients with colorectal liver metastases (CRLM), in close proximity to FLR critical structures (portal and/or hepatocaval confluence), having more than three criteria of Fong Clinical Risk Score for CRLM were approved by Ethical Comitee for Simultaneous PVE and Transarterial Chemoembolization with Degradable Starch Microspheres (DSM-TACE). For those patients, SIMULTA-NEOUSLY with standard PVE, was performed